FDA approves Lilly diabetes drug that helps patients lose weight
The drug has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster, with potential annual sales in the billions of dollars.
Diabetes
Lilly says experimental drug helped patients lose up to 22% of body weight
The drug, called tirzepatide, has been closely watched by medical professionals and is viewed by financial analysts as possible blockbuster, with potential annual sales in the billions of dollars.
House passes $35-a-month insulin cap as Dems seek wider bill
The Affordable Insulin Now Act will serve as a political vehicle to rally Democrats and force Republicans who oppose it into uncomfortable votes ahead of the midterms.
Limits on insulin costs revived in push for Senate action
Nearly 30 million Americans have diabetes, and more than 6 million use insulin to keep their blood sugars under control. It’s an old drug, refined over the years, that has seen relentless price increases.
Lilly buys California diabetes biotech in deal potentially worth $1 billion
The Indianapolis-based drugmaker said the deal to buy Protomer Technologies could be worth up to $1 billion if the technology meets certain milestones. Lilly did not say how much it was paying up front in cash.
U.S. deaths from heart disease, diabetes climbed amid pandemic
Data released this week show the biggest increases in the death rates for heart disease and diabetes in at least 20 years.
Lilly-funded partnership putting dent in diabetes in Indy neighborhoods
So far, the program has enrolled 275 people with diabetes. Health workers in the neighborhoods have completed more than 2,300 check-ins with them—helping them set up doctors’ visits, coaching them on how to shop for food, and helping them with dozens of related problems, from transportation needs to medical insurance.
Lilly adding two more insulin options to discount program
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
Lilly launches awareness campaign for insulin discount options
Under fire from politicians, patients and health care advocates over the price of insulin, Eli Lilly and Co. announced a campaign Thursday morning to raise awareness of cost-saving options for the drug.
Lilly begins selling half-price version of popular Humalog insulin
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
Harvard study involving Anthem unit finds older insulins are both safe, cheaper
Increasingly, top researchers are questioning whether drugs such as Lantus from Sanofi, Levemir and Novolog from Novo Nordisk A/S, and Humalog from Eli Lilly and Co. are really needed for many patients.
Hunger, food insecurity continue to vex Indiana residents
In Indiana, one million people face food insecurity, and in Indianapolis the number is approaching nearly 175,000—or more than 18 percent of the population.
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Roche using data-driven diagnostic tools to reshape patient care
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
Q&A: What’s behind the growing scrutiny of insulin prices?
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
Crawfordsville startup CorVus fattens pigs for science
The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
Major health initiative targets 3 Indianapolis neighborhoods with high diabetes rates
A five-year, $7 million program is led and supported by a coalition of local health institutions, including Eli Lilly and Co., Fairbanks School of Public Health and Eskenazi Health. It is based on a model that Lilly has used in other countries.
IndyGo’s daunting task: Turn drivers into health fanatics
Since starting a wellness program in 2010, IndyGo has seen employee participation climb from just a few, skeptical workers to 97 percent of the workforce.
Roche’s struggling diabetes unit looks toward ‘monster’ for boost
Roche Holding AG—the Basel, Switzerland-based parent of Indianapolis-based Roche Diagnostics—has enlisted a little green gremlin to help rescue its diabetes business after a decade of declining sales.
Lawsuit accuses Lilly of using kickbacks to boost insulin sales
A recently unsealed suit accuses the Indianapolis-based drugmaker of offering free nursing services to doctors to induce them to prescribe the company’s products.